The National Institutes of Health allocated about $15 million in funding to 13 two-year research initiatives creating 3-D microphysiological system platforms that model human disease.
The 3-D tissue models will be used to improve the study of investigational drugs, as medicines often fail in human trials after displaying promise in both cell and animal research models.
"The goal is for these tissue chips to provide more accurate platforms to understand diseases, and to be more predictive of the human response to drugs than current research models, thereby improving the success rate of candidate drugs in human clinical trials," said Christopher Austin, MD, director of the NIH's National Center for Advancing Translational Sciences' Tissue Chip for Drug Screening program.
More than 60 percent of experimental drugs fail in clinical trials.
To see a full list of awardees, click here.
More articles on supply chain:
Teva to sell contraceptive device business for $1.1B, divest remaining women's health assets
FDA reapproves leukemia drug 7 years after pulled from market
Supply chain inefficiencies leave $23B in potential savings on the table for hospitals